Hexylcaine

DB00473ApprovedWithdrawnSmall molecule

Hexylcaine hydrochloride is also known as cyclaine and osmocaine. It is a short acting local anesthetic that acts through inhibition of sodium channels. Patients experience an overdose may present with... Patients experience an overdose may present with headache, tinnitus, numbness and tingling around the mouth and tongue, convulsions, inability to breathe, and decreased heart function.

Mechanism: Hexyl caine acts mainly by inhibiting sodium influx through voltage gated sodium channels in the neuronal cell membrane of peripheral nerves. When the influx of sodium is interrupted, an action potential cannot arise and signal conduction is thus inhibited. The receptor site is thought to be located at the cytoplasmic (inner) portion of the sodium channel.
Curator reviewed
Primary indication: Used as a local anesthetic for surface application, infiltration or nerve blockCurator reviewed
Formula / weight: C₁₆H₂₃NO₂ · 261.3593 g/mol (avg)

Resolves to

Compound

UNII511IU0826ZCAS532-77-4ChEMBLCHEMBL1197ChEBI34791PubChem10770KEGGC14172

Clinical / RWD

RxNorm26879PharmGKBPA164746489

Structure

InChIKeyDKLKMKYDWHYZTD-UHFFFAOYSA-NSMILESCC(CNC1CCCCC1)OC(=O)C1=CC=CC=C1

Targets

Q14524SCN5AQ9Y5Y9SCN10A

What you can answer from here — as of September 13, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Hexylcaine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account